Logotyp: till Uppsala universitets webbplats

uu.sePublikationer från Uppsala universitet
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Interactions of GLP-1 peptide analogues with the permeation enhancer sodium caprate: Effect of lipidation and implications for oral delivery
(Engelska)Manuskript (preprint) (Övrigt vetenskapligt)
Abstract [en]

Oral peptide delivery increasingly relies on permeation enhancers (PEs), but how enhancer self-assembly couples to peptide self-assembly and co-assembly remains poorly understood. Here, we investigated the interactions between glucagon-like peptide-1 (GLP-1) analogues and the permeation enhancer sodium caprate (C10), with emphasis on how peptide lipidation and enhancer self-assembly control peptide availability for absorption. A non-lipidated analogue (J211), two mono-lipidated analogues (J229 and semaglutide), and a bis-lipidated analogue (MEDI7219) were characterized by 1H NMR spectroscopy, diffusion NMR, small-angle X-ray scattering (SAXS), circular dichroism (CD) and all-atom molecular dynamics (MD) simulations. In deuterated buffer, the peptides formed distinct oligomeric states with the size ranking semaglutide > J211 > J229 ≈ MEDI7219, while retaining predominantly α-helical secondary structure. C10 underwent a marked colloidal transition with the formulation conditions, forming non-spherical micelles at pD 8.5 and vesicular aggregates at pD 7.4 in fasted-state simulated intestinal fluid (FaSSIF-V2). Under alkaline micellar conditions, C10 associated with all peptides and remodeled the larger oligomers, J211 and semaglutide, by loosening peptide-peptide packing without major changes in global dimensions or helicity. Under near-neutral biorelevant conditions, peptide-C10 co-assembly became strongly peptide dependent. MEDI7219 showed the weakest association with C10 aggregates and retained the largest unbound fraction, whereas semaglutide and J229 had the most bound fraction. This ranking correlated to previously observed intestinal absorption ranking in vivo. These results show that peptide absorption is impacted by the coupled equilibria between peptide self-assembly, enhancer colloidal state, and peptide bound versus unbound fractions.

Nyckelord [en]
GLP-1 receptor agonists, sodium caprate, self-assembly, permeation enhancer, Oral peptide delivery
Nationell ämneskategori
Farmaceutiska vetenskaper
Forskningsämne
Farmaceutisk vetenskap
Identifikatorer
URN: urn:nbn:se:uu:diva-595345ISRN: SSRN 7129092DOI: 10.2139/ssrn.7129092OAI: oai:DiVA.org:uu-595345DiVA, id: diva2:2091660
Forskningsfinansiär
Vinnova, 2019-00048Tillgänglig från: 2026-08-12 Skapad: 2026-08-12 Senast uppdaterad: 2026-08-20
Ingår i avhandling
1. Effects of Peptide Molecular Properties and Permeation Enhancement on Oral Absorption
Öppna denna publikation i ny flik eller fönster >>Effects of Peptide Molecular Properties and Permeation Enhancement on Oral Absorption
2026 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Oral delivery of therapeutic peptides remains a pharmaceutical challenge because peptides are susceptible to gastrointestinal degradation and have poor permeability across the intestinal epithelium. Permeation enhancers (PEs), such as sodium caprate (C10), can improve intestinal uptake, but oral bioavailability remains low and variable. Even among structurally related peptides, the extent of absorption may differ following co-administration with the same PE, and the underlying mechanisms remain incompletely understood.

This thesis aimed to determine how peptide molecular properties and interactions with C10 impact intestinal absorption. The translational relevance of used in vitro and ex vivo permeability models were assessed. The effects of backbone modification and lipidation on peptide stability and absorption were studied. Peptide self-assembly, peptide–C10 interactions; and peptide interactions with a model cell membrane were examined. Four GLP-1 peptide analogues were evaluated: non-lipidated J211, mono-lipidated J229 and semaglutide, and bis-lipidated MEDI7219.

Comparative studies in Caco-2 monolayers, rat jejunal Ussing chambers, rats, and pigs showed that C10-mediated enhancement in vivo was concentration dependent and transient. In contrast, the in vitro and ex vivo models did not reproduce this pattern at physiologically relevant C10 concentrations, reflecting limitations including the absence of vascular clearance and epithelial recovery.

In rat intraduodenal studies, C10 significantly increased absorption of four peptides, but the extent varied markedly. MEDI7219 achieved the highest absolute bioavailability (17.3%), compared with 7.5% for J211, 4.0% for J229, and 2.0% for semaglutide. Extensive backbone modification conferred resistance to pancreatin-mediated degradation, whereas semaglutide was degraded. C10 partially improved semaglutide stability, indicating limited protection against luminal proteolysis in addition to enhanced epithelial transport.

Biophysical characterisation and molecular-dynamics simulations showed that the peptides differed in self-association, interaction with C10 aggregates, and membrane engagement. MEDI7219 showed the weakest apparent association with C10 aggregates and retained the highest apparent mobility, consistent with a greater freely available or rapidly exchanging fraction. It also exhibited the deepest and most stable lipid-tail insertion into the model cell membrane. These properties were consistent with its superior intestinal absorption.

C10-enabled oral peptide absorption is governed not only by epithelial permeabilisation, but also by peptide stability, self-assembly, peptide–enhancer interactions, and membrane association.

Ort, förlag, år, upplaga, sidor
Uppsala: Acta Universitatis Upsaliensis, 2026. s. 115
Serie
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy, ISSN 1651-6192 ; 407
Nyckelord
Permeation Enhancer, Sodium Caprate, Oral Peptide Delivery, Lipidation, GLP-1 Peptide Analogue, Bioavailability
Nationell ämneskategori
Farmaceutiska vetenskaper
Forskningsämne
Farmaceutisk vetenskap
Identifikatorer
urn:nbn:se:uu:diva-596050 (URN)978-91-513-2932-1 (ISBN)
Disputation
2026-10-09, Room IV, University Main Building, Biskopsgatan 3,, Uppsala, 13:15 (Engelska)
Opponent
Handledare
Forskningsfinansiär
Vinnova, 2019-00048
Tillgänglig från: 2026-09-17 Skapad: 2026-08-20 Senast uppdaterad: 2026-09-17

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltexthttps://papers.ssrn.com/sol3/papers.cfm?abstract_id=7129092
Farmaceutiska vetenskaper

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 92 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf